Welcome to the BioNanoEngineering group directed by Professor Benjamin Thierry. The group is based at the Future Industries Institute at the UniSA, and is a node of the ARC Centre of Excellence for Convergent Bio-Nano Science and Technology.
Our research activities focus at the interface of bioengineering, materials science, nanoscience, and medicine and our main objective is to develop and implement novel biodiagnostic and prognostic technologies, with a focus on cancer with poor prognosis. We also aim to develop, in collaboration with biomedical researchers, technologies able to provide new insights about important biological processes, including the metastatic processes.
A major aspect of our translational research is the design of solid state biosensing approaches based on cutting edge nano/microtechnology principles to isolate and/or detect rare cells and cancer biomarkers from biological samples such as blood and resected tissues. In close collaborations with clinicians and cancer biologists, we also aim to obtain improved mechanistic understanding of the penetration of therapeutic and diagnostic agents inside tumour tissues and to translate these insights into more efficient diagnostic and therapeutic approaches. To this end, we are developing cutting-edge “organs-on-a-chip” technologies that bridge the gap between engineering and medicine, and allow us to mimic and study complex organs/tissues such as vascularized tumours or the intestinal epithelium. Our translational research focus is illustrated by the establishment of Ferronova Ltd, a spin-off company aimed at the clinical development of our cancer diagnostic probe technology.
A key aspect of our research is is that it is carried out in close collaboration with end-users, including industry partners and clinicians.